Philadelphia chromosome‐positive acute myeloid leukemia (Ph + AML) is a rare type of AML with a low survival rate and poor prognosis. We first report a Ph + AML patient who remained in long‐term remission after the combination of flumatinib and venetoclax, which could provide corresponding treatment ideas for clinical practice. The figure shows the treatment process of the patient and the dynamic changes in blood cell count during venetoclax and flumatinib. The BCR::ABL1 transcript was negative after two courses of the combination of venetoclax anf flumatinib. No serious adverse events occurred during the treatment, although hematological toxicity was observed. [ABSTRACT FROM AUTHOR]